Lead Product(s) : EG110A,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : EG110A,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Human Oral Epithelium Stem Cell,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Fondazione IRCCS Ca' Granda | University of Modena and Reggio Emilia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : Autologous Human Oral Epithelium Stem Cell,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Fondazione IRCCS Ca' Granda | University of Modena and Reggio Emilia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mentha Piperita Oil,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Integrative Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 14, 2021
Lead Product(s) : Mentha Piperita Oil,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Integrative Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tranexamic Acid,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : BC Support Unit | Michael Smith Foundation for Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2020
Lead Product(s) : Tranexamic Acid,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : BC Support Unit | Michael Smith Foundation for Health Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SI-722,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK and Safety of SI-722 in IC/BPS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2019
Lead Product(s) : SI-722,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tamsulosin,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Post-operative Urinary Retention (POUR) Following Thoracic Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2018
Lead Product(s) : Tamsulosin,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rec 0/0438,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 29, 2018
Lead Product(s) : Rec 0/0438,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Litoxetine,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2018
Lead Product(s) : Litoxetine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nerindocianine,Inapplicable
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2017
Lead Product(s) : Nerindocianine,Inapplicable
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Microcannula Harvest Adipose,Sodium Chloride
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Terry, Glenn C., M.D.
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 10, 2016
Lead Product(s) : Microcannula Harvest Adipose,Sodium Chloride
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Terry, Glenn C., M.D.
Deal Size : Inapplicable
Deal Type : Inapplicable